Indications and contraindications to platelet-rich plasma injections in musculoskeletal diseases in case of infectious, oncological and haematological comorbidities: A 2025 formal consensus from the GRIIP (International Research Group on Platelet Injectio

Fiche publication

Date publication

avril 2025

Journal

Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ORNETTI Paul

Tous les auteurs :
Eymard F, Louati K, Noel É, Abouqal R, Adam P, Allali F, Antherieu G, Caers J, Cognasse F, Collado H, Darrieutort-Laffite C, Frère C, Frey A, Gavillet M, Gremeaux V, Heiblig M, Jerusalem G, Joly C, Kaux JF, Lamontagne M, Leclerc M, Léonard P, Lepeule R, Lopez-Trabada-Ataz D, Magalon J, Michel F, Ornetti P, Oury C, Pons-Tostivint E, Real F, Robert G, Sanchez M, Silvestre A, Bard H

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40260684

Résumé

Platelet-rich plasma (PRP) could be a vector for certain diseases, and its composition may vary by pathologic condition. The main comorbidities that could affect PRP composition are infectious, oncologic and haematologic. In addition to potential alteration of clinical response, these pathologies could have a significant impact on the local tolerance of PRP as well as a risk of disease dissemination to the injection site. To date, there are few specific recommendations related to these comorbidities to guide clinicians. Therefore, the International Research Group on Platelet Injections (GRIIP) supported a consensus project to develop these recommendations.